Overview
- Includes supplementary material: sn.pub/extras
Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 172)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (10 chapters)
-
Front Matter
Keywords
About this book
Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components? Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow’s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book.
Editors and Affiliations
Bibliographic Information
Book Title: Targeted Interference with Signal Transduction Events
Editors: Bernd Groner
Series Title: Recent Results in Cancer Research
DOI: https://doi.org/10.1007/978-3-540-31209-3
Publisher: Springer Berlin, Heidelberg
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer-Verlag Berlin Heidelberg 2007
Hardcover ISBN: 978-3-540-31208-6Published: 05 June 2007
Softcover ISBN: 978-3-642-06834-8Published: 18 November 2010
eBook ISBN: 978-3-540-31209-3Published: 09 August 2007
Series ISSN: 0080-0015
Series E-ISSN: 2197-6767
Edition Number: 1
Number of Pages: IX, 188
Topics: Cancer Research, Oncology, Molecular Medicine